Painful Intercourse: Drugs That Cause It and Drugs That Treat It

What Painful Intercourse Actually Means Clinically

Dyspareunia is recurrent or persistent genital pain that occurs just before, during, or after penetrative sexual activity. The International Society for the Study of Vulvovaginal Disease classifies it by location: superficial (introital), deep, or mixed. Superficial dyspareunia most often points to vulvovaginal atrophy, vestibulodynia, or infection. Deep dyspareunia raises concern for endometriosis, pelvic inflammatory disease, or uterine pathology.

A 2014 cross-sectional analysis published in BJOG estimated that 17.1% of women globally report dyspareunia, with prevalence climbing to 45% in women within three years of menopause [1]. The condition is not simply "dryness." Tissue thinning, loss of elasticity, reduced blood flow, and altered vaginal pH all contribute. Understanding whether a medication is driving these tissue-level changes or whether pharmacotherapy can reverse them is the foundation of rational treatment.

Medications That Cause or Worsen Painful Intercourse

Several commonly prescribed drug classes reduce vaginal lubrication, thin mucosal tissue, or alter hormonal signaling in ways that produce or intensify dyspareunia. Identifying these medications is the first clinical step before adding new treatments.

Aromatase inhibitors (anastrozole, letrozole, exemestane) suppress residual estrogen production in postmenopausal breast cancer survivors. In the ATAC trial (N=9,366), musculoskeletal and sexual side effects were reported by 31% of women on anastrozole versus 19% on tamoxifen [2]. Vaginal dryness and dyspareunia are the most common reasons patients discontinue aromatase inhibitor therapy early.

Selective serotonin reuptake inhibitors (SSRIs) decrease genital arousal and lubrication through serotonergic inhibition of nitric oxide pathways. A systematic review in the Journal of Clinical Psychopharmacology found that sexual dysfunction occurs in 40-65% of SSRI users, with reduced lubrication and subsequent pain affecting roughly one in four women on these agents [3].

Combined hormonal contraceptives lower free testosterone and increase sex hormone-binding globulin (SHBG). Some formulations suppress vulvar and clitoral blood flow. The effect is dose-dependent and partially reversible, though elevated SHBG can persist months after discontinuation.

GnRH agonists and antagonists (leuprolide, elagolix) create a hypoestrogenic state to treat endometriosis or fibroids. Dyspareunia rates in the Phase III Elaris EM-I and EM-II trials reached 15-20% in the elagolix-alone arms [4].

Antihistamines and anticholinergics dry mucosal membranes systemically. Diphenhydramine, oxybutynin, and tricyclic antidepressants all reduce vaginal secretions through muscarinic receptor blockade.

Medroxyprogesterone acetate (Depo-Provera) suppresses ovarian estradiol production and can thin vaginal epithelium over years of use, particularly in younger women.

First-Line Treatment: Low-Dose Vaginal Estrogen

For dyspareunia caused by vulvovaginal atrophy or GSM, low-dose vaginal estrogen remains the gold standard. The 2020 NAMS position statement endorses it as first-line pharmacotherapy for symptomatic GSM when lubricants alone prove inadequate [5].

Three formulations are available in the United States: estradiol cream (Estrace, 0.01%), the estradiol vaginal ring (Estring, 7.5 mcg/day release), and estradiol vaginal tablets (Vagifem/Yuvafem, 10 mcg). All three deliver estrogen locally with minimal systemic absorption. Serum estradiol levels remain within the postmenopausal range for most patients.

The efficacy data are strong. A Cochrane review of 30 RCTs (N=6,235) found that low-dose vaginal estrogen significantly improved dyspareunia scores compared with placebo, with a standardized mean difference of -0.43 (95% CI -0.58 to -0.28) at 12 weeks [6]. Vaginal maturation index improved by 25-40 percentage points, and pH dropped from 6.0-7.0 back toward the premenopausal range of 3.5-4.5.

Patients typically notice reduced pain within 4-6 weeks, with maximum benefit at 12 weeks. The standard regimen is daily application for two weeks followed by twice-weekly maintenance. Side effects are uncommon but include vaginal spotting (3-5%) and breast tenderness (<2%).

For breast cancer survivors on aromatase inhibitors, the safety of vaginal estrogen remains debated. The 2024 ASCO/ACOG/NAMS joint statement notes that ultra-low-dose vaginal estrogen (4 mcg tablets or the ring) does not meaningfully increase serum estradiol in most patients, though shared decision-making with the oncologist is required [7].

Ospemifene (Osphena): The Oral Alternative

Ospemifene is a selective estrogen receptor modulator (SERM) approved by the FDA in 2013 specifically for moderate-to-severe dyspareunia due to vulvovaginal atrophy. It acts as an estrogen agonist in vaginal tissue while behaving as a partial antagonist in breast and endometrial tissue.

The key Phase III trial (N=826) randomized postmenopausal women with moderate-to-severe dyspareunia to ospemifene 60 mg daily or placebo for 12 weeks [8]. The ospemifene group showed a 1.5-point reduction in dyspareunia severity (on a 4-point scale) versus 1.2 points for placebo (P<0.001). More striking: 72% of ospemifene-treated patients reported clinically meaningful improvement versus 48% on placebo.

Long-term data from a 52-week open-label extension confirmed sustained efficacy. Vaginal dryness scores continued to improve through week 52. Hot flashes were the most common side effect (7.5% vs. 2.6% placebo). There was no increase in endometrial hyperplasia or breast cancer incidence over the observation period.

Ospemifene is contraindicated in women with undiagnosed vaginal bleeding, known or suspected breast cancer, or active venous thromboembolism. It is the only oral, non-estrogen prescription specifically indicated for GSM-related dyspareunia.

Intravaginal Prasterone (Intrarosa): The DHEA Approach

Prasterone (dehydroepiandrosterone, DHEA) 6.5 mg is an intravaginal insert approved in 2016 for moderate-to-severe dyspareunia in postmenopausal women. Unlike exogenous estrogen, prasterone relies on intracrine conversion: vaginal cells metabolize DHEA into both estrogens and androgens locally without raising systemic hormone levels above postmenopausal thresholds.

Two Phase III trials established its efficacy. In the ERC-238 study (N=481), prasterone reduced dyspareunia severity by 1.27 points at 12 weeks versus 0.87 for placebo (P=0.013) [9]. Vaginal cell maturation improved by 9.3 percentage points. The co-primary endpoint of parabasal cell reduction also reached significance.

The practical advantage of prasterone is its classification as a "non-estrogen" therapy, making it suitable for some women who decline or cannot use estrogen products. Serum estradiol, estrone, and testosterone remained within postmenopausal ranges at all time points in clinical trials. Vaginal discharge is the most common complaint (6%), related to the melting of the waxy insert.

Systemic Hormone Therapy for Moderate-to-Severe Cases

When dyspareunia coexists with vasomotor symptoms (hot flashes, night sweats) or other GSM manifestations, systemic estrogen therapy addresses multiple complaints simultaneously. The 2022 Endocrine Society guideline recommends systemic HT for symptomatic women under age 60 or within 10 years of menopause onset [10].

Standard regimens include transdermal estradiol 0.025-0.05 mg/day (patch) or oral estradiol 0.5-1.0 mg daily, always combined with a progestogen in women with an intact uterus. Conjugated equine estrogens 0.3-0.45 mg are also effective but increasingly replaced by bioidentical estradiol.

The Women's Health Initiative (WHI) Estrogen-Alone trial (N=10,739) demonstrated that conjugated equine estrogens reduced GSM symptoms in the estrogen-only arm, with no increased breast cancer risk over 7.2 years of follow-up in hysterectomized women [11]. The risk-benefit calculation remains favorable for symptomatic women in the "timing hypothesis" window.

Systemic therapy is not first-line for isolated dyspareunia because local treatments achieve vaginal concentrations 100-fold higher than systemic doses without the thrombotic or cardiovascular considerations. However, for women with multi-symptom GSM, systemic HT may be more practical than layering multiple topical products.

Testosterone for Dyspareunia: Current Evidence

Vaginal testosterone 300-500 mcg has been studied in breast cancer survivors who cannot use estrogen. A pilot RCT (N=45) published in the Annals of Oncology found that intravaginal testosterone cream improved dyspareunia scores without raising serum estradiol above postmenopausal thresholds [12]. Vaginal maturation improved and pH decreased.

This remains off-label use. Compounded vaginal testosterone in bases like VersaBase is available through specialty pharmacies but lacks FDA approval for this indication. The 2019 Global Consensus Position Statement on testosterone therapy endorsed only systemic testosterone for hypoactive sexual desire disorder, not for dyspareunia directly.

Non-Hormonal Pharmacotherapy Options

For women who decline all hormonal approaches, limited pharmacologic alternatives exist. Vaginal moisturizers containing hyaluronic acid or polycarbophil (Replens) provide temporary symptom relief but do not reverse atrophy.

Lidocaine 4% aqueous solution applied to the vestibule 3 minutes before penetration was studied in a randomized trial of 46 postmenopausal women and reduced insertional pain by 50% compared with saline [13]. This is a practical bridge therapy while hormonal treatments take effect.

Gabapentin 300-600 mg nightly and amitriptyline 10-25 mg have shown benefit in provoked vestibulodynia (a distinct entity from atrophic dyspareunia), though evidence comes from small trials and case series rather than large RCTs.

Pelvic floor physical therapy is guideline-recommended as an adjunct for all subtypes of dyspareunia. It addresses the secondary vaginismus and muscle guarding that develop as pain-avoidance reflexes, regardless of the original trigger.

Drug-Induced Dyspareunia: Management Algorithm

The clinical approach to medication-induced dyspareunia follows a stepwise framework:

Step 1: Identify the culprit. Review all current medications against the known offender list. SSRI-related dyspareunia warrants a trial of bupropion substitution or dose reduction. Antihistamine-related dryness may respond to switching from first-generation to second-generation agents.

Step 2: Reduce or substitute when safe. For aromatase inhibitor patients, switching from anastrozole to letrozole (or vice versa) occasionally helps, though data supporting differential sexual side effects between agents are thin.

Step 3: Add local treatment. Vaginal estrogen or prasterone addresses tissue atrophy regardless of the systemic cause. For AI patients, prasterone or ultra-low-dose vaginal estrogen with oncology co-management is appropriate.

Step 4: Layer systemic therapy if needed. Ospemifene provides an oral non-estrogen option that can supplement local therapy in refractory cases.

Step 5: Escalate. Refer to a sexual medicine specialist or vulvovaginal disease clinic if pain persists beyond 12 weeks of optimized therapy.

"For patients on aromatase inhibitors experiencing dyspareunia, we initiate vaginal DHEA first and reserve ultra-low-dose estrogen for those who fail to respond after 8-12 weeks." This reflects the approach outlined in the NAMS 2020 GSM position statement [5].

When to Suspect Something Beyond Medication Effects

Not all dyspareunia is hormonal or drug-induced. Red flags that require additional workup include: unilateral pain localized to a specific anatomic structure, new-onset deep dyspareunia after age 40 (raises concern for ovarian pathology), postcoital bleeding, or associated symptoms like pelvic pressure or bowel/bladder dysfunction.

"New-onset deep dyspareunia combined with abnormal uterine bleeding in any woman over 40 warrants transvaginal ultrasound as a minimum initial investigation." This aligns with the ACOG Practice Bulletin on chronic pelvic pain [14].

Endometriosis causes deep dyspareunia in approximately 50% of affected women and requires different management (GnRH antagonists, progestins, or surgical excision). Vulvodynia and vestibulodynia are neuropathic pain conditions that mimic hormonal dyspareunia but require neuromodulatory treatment rather than estrogen replacement.

Comparing Treatment Options: Efficacy Data Head-to-Head

No single RCT directly compares all available therapies. Indirect comparisons from network meta-analyses suggest:

Vaginal estrogen and intravaginal prasterone produce similar improvements in dyspareunia severity (approximately 1.0-1.3 point reduction on a 4-point scale at 12 weeks). Ospemifene produces slightly less vaginal maturation improvement than topical estrogen but offers the convenience of a once-daily oral tablet. The 2021 network meta-analysis in Maturitas (encompassing 28 trials and 8,311 participants) found no statistically significant difference in dyspareunia outcomes between vaginal estrogen, prasterone, and ospemifene at 12 weeks [15].

Patient preference often determines the choice. Women who dislike vaginal inserts prefer ospemifene. Women who want minimal systemic absorption prefer the vaginal ring. Women concerned about estrogen exposure prefer prasterone. All three categories have strong efficacy data supporting their use.

Onset of action is comparable across agents: initial improvement at 4 weeks, clinically meaningful relief by 8-12 weeks. Patients should be counseled that 12 weeks represents the minimum adequate trial before declaring treatment failure.